Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.57 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.56 |
| ▸ | ACACB | O00763 | 12/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.51 |
| ▸ | ACACA | Q13085 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15773082 | 0.85 | LIPG (0.58) | LIPGPAX8ACACBKCNH2TMEM97 | |
| SCHEMBL19636021 | 0.82 | PAX8 (0.54) | LIPGPAX8ACACBKCNH2TMEM97 | |
| SCHEMBL17244764 | 0.80 | ACACB (0.51) | ACACBACACA | |
| SCHEMBL4716937 | 0.79 | TMEM97 (0.57) | LIPGKCNH2TMEM97MEN1KMT2A | |
| SCHEMBL5319979 | 0.78 | ALDH1A1 (0.65) | MEN1KMT2A | |
| SCHEMBL1547203 | 0.78 | ACACB (0.58) | ACACBACACA | |
| SCHEMBL1547741 | 0.78 | ACACB (0.58) | ACACBACACA | |
| SCHEMBL2712266 | 0.77 | LIPG (0.49) | LIPGPAX8ACACBKCNH2MEN1 | |
| SCHEMBL2712262 | 0.77 | LIPG (0.49) | LIPGPAX8ACACBKCNH2MEN1 | |
| SCHEMBL10187974 | 0.76 | KMT2A (0.62) | ACACBACACAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329542-B2 | HBV RNAse H purification and enzyme inhibitors | SAINT LOUIS UNIVERSITY (US) | 2019-06-25 | — | — | US | disclosed |
| US-20170335296-A1 | HBV RNASE H PURIFICATION AND ENZYME INHIBITORS | SAINT LOUIS UNIVERSITY (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170335296-A1 | HBV RNASE H PURIFICATION AND ENZYME INHIBITORS | RNASEH1, RNASE1, RNASEL | LIPG 937/4885PAX8 4118/4885ACACB 2190/4885 |
| US-10329542-B2 | HBV RNAse H purification and enzyme inhibitors | RNASEH1, RNASE1, RNASEL | LIPG 937/4885PAX8 4118/4885ACACB 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.